FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, namely to therapy, and can be used for treatment of scleroderma. For this purpose, a therapeutically efficient quantity of type I interferon (IFN) antagonist, where the said antagonist is represented by an antibody, is introduced to a patient in need. The group of inventions also relates to a method of reducing intensity of one or more symptoms, associated with scleroderma.
EFFECT: application of type I interferon antagonist, namely the antibody, makes it possible to suppress transmission of IFN signal with the participation of άIFN receptor, which substantially reduces the probability of development and severity of inflammatory disease of skin and contributes to skin recovery.
20 cl, 8 ex, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACODYNAMIC MARKERS, INDUCED BY ALPHA INTERFERON | 2007 |
|
RU2527068C2 |
| TREATING CANCER WITH IMMUNOSTIMULANTS | 2015 |
|
RU2740288C2 |
| IMMUNE ENHANCING AGENT FOR TREATING A MALIGNANT NEOPLASM WITH USING AN ALLERGIN-1 ANTAGONIST | 2016 |
|
RU2734777C2 |
| ILT17 ANTIBODY | 2012 |
|
RU2599450C2 |
| ANTI-ICOS ANTIBODIES AND THEIR APPLICATION IN TREATMENT OF ONCOLOGICAL, TRANSPLANTATION-ASSOCIATED AND AUTOIMMUNE DISEASES | 2008 |
|
RU2549701C2 |
| ANTI-IFNAR1 ANTIBODIES WITH LOWER LIGAND Fc AFFINITY | 2009 |
|
RU2556125C2 |
| ILT17 ANTIBODY | 2006 |
|
RU2456298C2 |
| TYPE I INTERFERON MEDIATED DISORDERS | 2020 |
|
RU2815973C2 |
| METHODS AND COMPOSITIONS FOR AUTOIMMUNE AND INFLAMMATORY DISEASES TREATMENT | 2012 |
|
RU2639540C2 |
| METHODS OF INHIBITING TUMOR GROWTH BY IL-6 RECEPTOR ANTAGONIZATION | 2012 |
|
RU2648150C2 |
